VIPDOMET 12.5/500; 12.5 mg alogliptin (as benzoate) / 500 mg metformin hydrochloride film-coated tablets blister pack

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

metformin hydrochloride, Quantity: 500 mg; alogliptin benzoate, Quantity: 17 mg (Equivalent: alogliptin, Qty 12.5 mg)

Disponível em:

Takeda Pharmaceuticals Australia Pty Ltd

DCI (Denominação Comum Internacional):

Alogliptin benzoate,Metformin hydrochloride

Forma farmacêutica:

Tablet, film coated

Composição:

Excipient Ingredients: microcrystalline cellulose; mannitol; magnesium stearate; titanium dioxide; hypromellose; crospovidone; povidone; purified talc; iron oxide yellow

Via de administração:

Oral

Unidades em pacote:

196, 20, 120, 14, 28, 112, 60, 56, 200, 98, 180, 10

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

VIPDOMET is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,VIPDOMET can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

Resumo do produto:

Visual Identification: Pale yellow, oblong, biconvex, film-coated tablet with 12.5/500 debossed on one side and 322M debossed on the other side; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Status de autorização:

Registered

Data de autorização:

2013-10-22